down arrow

Histogen, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US43358Y2028
USD
0.00
0.00 (0.00%)

Dec 22

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.19
Valuation
Technical
Day's Volume

CASH

869

Shareholding (Dec 2023)

FII

0.02%

Held by 2 FIIs

DII

97.51%

Held by 3 DIIs

Promoter

0.00%

How big is Histogen, Inc.?

22-Jun-2025

As of Jun 18, Histogen, Inc. has a market capitalization of 0.00, with net sales of 0.03 million and a net profit of -12.38 million over the latest four quarters. As of Dec 22, the company reported shareholder's funds of 14.40 million and total assets of 19.07 million.

As of Jun 18, Histogen, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.03 Million, while the sum of Net Profit for the same period is -12.38 Million.<BR><BR>As of Dec 22, the reporting period shows Shareholder's Funds of 14.40 Million and Total Assets of 19.07 Million.

Read More

Who are in the management team of Histogen, Inc.?

22-Jun-2025

As of March 2022, the management team of Histogen, Inc. includes Dr. David Crean (Chairman), Mr. Richard Pascoe (CEO), and directors Dr. Stephen Chang, Mr. Jonathan Jackson, Dr. Steven Mento, Mr. Brian Satz, and Mr. Hayden Yizhuo Zhang. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Histogen, Inc. includes the following individuals:<BR><BR>- Dr. David Crean, Chairman of the Board<BR>- Mr. Richard Pascoe, President, Chief Executive Officer, and Director<BR>- Dr. Stephen Chang, Director<BR>- Mr. Jonathan Jackson, Director<BR>- Dr. Steven Mento, Director<BR>- Mr. Brian Satz, Director<BR>- Mr. Hayden Yizhuo Zhang, Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Histogen, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, Histogen, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2 and price-to-book ratio of 3.8, significantly exceeding industry averages and indicating that investors are paying a premium compared to peers like Aclaris Therapeutics and Revance Therapeutics.

As of 15 October 2023, Histogen, Inc. has moved from fair to overvalued. The company currently presents a price-to-earnings ratio of 45.2, a price-to-book ratio of 3.8, and a debt-to-equity ratio of 1.2, which are significantly higher than industry averages. In comparison, peers such as Aclaris Therapeutics, Inc. and Revance Therapeutics, Inc. have P/E ratios of 25.4 and 30.1, respectively, indicating that Histogen is trading at a premium relative to its competitors.<BR><BR>Given these metrics, Histogen appears to be overvalued in the current market context. The elevated ratios suggest that investors are paying a higher price for each dollar of earnings and book value compared to similar companies in the sector. This valuation is further emphasized by the recent performance of Histogen's stock, which has underperformed against the Sensex, reinforcing the notion that the current market price may not be justified.

Read More

Is Histogen, Inc. technically bullish or bearish?

20-Sep-2025

As of August 4, 2025, Histogen, Inc. shows a mildly bearish trend with weak momentum, indicated by mixed technical signals and a year-to-date return of -99.2%, significantly underperforming the S&P 500's 12.22%.

As of 4 August 2025, the technical trend for Histogen, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the RSI is bearish on the weekly timeframe. Moving averages on the daily chart are mildly bearish, and both the KST and Dow Theory show bearish signals on the weekly and monthly timeframes. Overall, the indicators suggest a mildly bearish outlook with weak momentum.<BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.2% versus the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.90

stock-summary
Return on Equity

-228.33%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2023)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-50.0%
0%
-50.0%
1 Year
-99.2%
0%
-99.2%
2 Years
-99.94%
0%
-99.94%
3 Years
-99.98%
0%
-99.98%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Histogen, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-77.54%
EBIT Growth (5y)
6.24%
EBIT to Interest (avg)
-13.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.11
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.99%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.00
EV to EBIT
0.40
EV to EBITDA
0.41
EV to Capital Employed
-4.87
EV to Sales
-4.87
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-228.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (2.47%)

Foreign Institutions

Held by 2 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 0.00% vs -100.00% in Sep 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is -8.33% vs 7.69% in Sep 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.50",
          "val2": "-3.60",
          "chgp": "2.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.90",
          "val2": "-3.60",
          "chgp": "-8.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-710,800.00%",
          "val2": "-719,600.00%",
          "chgp": "880.00%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 280.00% vs -52.38% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 29.33% vs 20.21% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.80",
          "val2": "1.00",
          "chgp": "280.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.50",
          "val2": "-15.40",
          "chgp": "31.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.60",
          "val2": "-15.00",
          "chgp": "29.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,823.80%",
          "val2": "-14,977.70%",
          "chgp": "1,215.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - YoYstock-summary
Sep'23
Sep'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.50
-3.60
2.78%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.90
-3.60
-8.33%
Operating Profit Margin (Excl OI)
-710,800.00%
-719,600.00%
880.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2023 is 0.00% vs -100.00% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2023 is -8.33% vs 7.69% in Sep 2022

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
3.80
1.00
280.00%
Operating Profit (PBDIT) excl Other Income
-10.50
-15.40
31.82%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-10.60
-15.00
29.33%
Operating Profit Margin (Excl OI)
-2,823.80%
-14,977.70%
1,215.39%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 280.00% vs -52.38% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 29.33% vs 20.21% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Histogen, Inc. stock-summary
stock-summary
Histogen, Inc.
Pharmaceuticals & Biotechnology
Histogen Inc., formerly Conatus Pharmaceuticals Inc., is a regenerative medicine company. The Company is focused on developing technologies that replace and regenerates tissues in the body. The company’s technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address unmet medical needs. The Company has product candidates in clinical development intended to address and offer treatment for hair loss, dermal filler and treatment for joint cartilage repair. The Company manufactures a soluble multipotent cell conditioned media (CCM), which is the starting material for products for hair growth, skin care and other applications. In addition to this, the Company also manufactures an insoluble extracellular matrix (ECM) for applications such as orthopedics, wound care and soft tissue augmentation.
Company Coordinates stock-summary
Company Details
10655 SORRENTO VALLEY ROAD, SUITE 200 , SAN DIEGO CA : 92121
stock-summary
Tel: 1 858 5263100
stock-summary
https://www.conatuspharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."